Nexalin Technology (NXL) Capital Expenditures (2026)
Nexalin Technology (NXL) posted quarterly Capital Expenditures of $49276.0 for Q1 2026.
Nexalin Technology (NXL) Capital Expenditures (2026) Analysis & Trends
Nexalin Technology's Capital Expenditures history runs 1 years deep, the most recent figure standing at $49276.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 497.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 202.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 488.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 195.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 66.90 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 84.70 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 100.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -74.39 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 87.50 Mn |
| 10 | Nexalin Technology | 7.00 Mn | 6.00 Mn | 8,897.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,276.00 |
| Mar 31, 2026 | 49,276.00 |